PT-141 Nasal Spray Safely Induces Erection in Both Healthy Men and ED Patients
Intranasal PT-141 (bremelanotide) safely induced erections in healthy men and Viagra-responsive ED patients in a double-blind placebo-controlled trial, validating melanocortin-based intranasal erectile dysfunction therapy.
Quick Facts
What This Study Found
Intranasal PT-141 induced dose-dependent erectile responses in both healthy men and Viagra-responsive ED patients in a double-blind, placebo-controlled trial, with rapid onset and acceptable safety — validating intranasal melanocortin ED therapy.
Key Numbers
How They Did This
Double-blind, placebo-controlled, dose-escalation study. PT-141 intranasal spray in healthy males and Viagra-responsive ED patients. Erectile response (RigiScan), pharmacokinetics, and safety measured.
Why This Research Matters
PT-141's intranasal delivery offers a non-invasive alternative to injections. Its brain-based mechanism helps patients where Viagra (which works on blood flow) is insufficient — addressing desire, not just mechanics.
The Bigger Picture
PT-141 later became FDA-approved as Vyleesi (for female sexual desire). This male ED study validated the intranasal melanocortin approach that informed its clinical development path.
What This Study Doesn't Tell Us
Viagra-responsive ED patients (mild ED). Results may differ in severe ED or Viagra-non-responders. Nausea at higher doses limits dose escalation.
Questions This Raises
- ?Can PT-141 help Viagra-non-responders?
- ?What is the optimal intranasal dose balancing efficacy and nausea?
- ?Could combination PT-141 + PDE5 inhibitor address both desire and blood flow?
Trust & Context
- Key Stat:
- Brain-based nasal spray Intranasal PT-141 induced erections through brain melanocortin receptors — a non-invasive alternative working through desire rather than blood flow
- Evidence Grade:
- Moderate evidence from a well-designed double-blind, placebo-controlled dose-escalation study in two relevant populations.
- Study Age:
- Published in 2004. PT-141 development continued, leading to FDA approval as Vyleesi (SC injection) for female sexual desire disorder in 2019.
- Original Title:
- Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.
- Published In:
- International journal of impotence research, 16(1), 51-9 (2004)
- Authors:
- Diamond, L E(4), Earle, D C(3), Rosen, R C(2), Willett, M S, Molinoff, P B
- Database ID:
- RPEP-00903
Evidence Hierarchy
Frequently Asked Questions
How is PT-141 different from Viagra?
Viagra works on blood flow to the penis. PT-141 works on the brain's desire centers through melanocortin receptors. It addresses WANTING to have sex, not just the physical mechanics.
Is a nasal spray practical for ED?
This study showed it works — rapid absorption, peak effect in 1-2 hours, and significant erectile responses. The nasal route is non-invasive and discreet.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00903APA
Diamond, L E; Earle, D C; Rosen, R C; Willett, M S; Molinoff, P B. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.. International journal of impotence research, 16(1), 51-9.
MLA
Diamond, L E, et al. "Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.." International journal of impotence research, 2004.
RethinkPeptides
RethinkPeptides Research Database. "Double-blind, placebo-controlled evaluation of the safety, p..." RPEP-00903. Retrieved from https://rethinkpeptides.com/research/diamond-2004-doubleblind-placebocontrolled-evaluation-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.